{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-058157","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.018735+00:00","generated_at":"2026-06-08T23:50:29.063176+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kura Oncology Q3 net loss $38.6M; cash $452.6M; ziftomenib trial enrollment on track for mid-2024","bullets":["Net loss $38.6M vs $35.5M YoY; R&D $29.3M; cash $452.6M provides runway to mid-2026.","Enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete 85 patients by mid-2024.","Preliminary data from 20 patients in KOMET-007 combination trial (ziftomenib + venetoclax/azacitidine or 7+3) expected early Q1 2024.","First patient dosed in FIT-001 trial of next-gen FTI KO-2806; collaboration with Mirati for combo with adagrasib in KRAS G12C-mutated NSCLC.","Brian Powl appointed Chief Commercial Officer in August 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-058157","json":"https://secwatch.observer/filing/0000950170-23-058157.json","markdown":"https://secwatch.observer/filing/0000950170-23-058157.md","text":"https://secwatch.observer/filing/0000950170-23-058157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000095017023058157/0000950170-23-058157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000095017023058157/kura-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:50:29.063176+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b547db107a64ab994b74c36715843e6c13bdae5","claim":"Kura Oncology, Inc. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"On November 2, 2023, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2023 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000095017023058157/0000950170-23-058157-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}